797 related articles for article (PubMed ID: 34380701)
21. Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis.
Christmann RB; Sampaio-Barros P; Stifano G; Borges CL; de Carvalho CR; Kairalla R; Parra ER; Spira A; Simms R; Capellozzi VL; Lafyatis R
Arthritis Rheumatol; 2014 Mar; 66(3):714-25. PubMed ID: 24574232
[TBL] [Abstract][Full Text] [Related]
22. High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.
Al-Adwi Y; Atzeni IM; Doornbos-van der Meer B; van der Leij MJ; Varkevisser RDM; Kroesen BJ; Stel A; Timens W; Gan CT; van Goor H; Westra J; Mulder DJ
EBioMedicine; 2023 Dec; 98():104883. PubMed ID: 37995465
[TBL] [Abstract][Full Text] [Related]
23. Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.
Antoniou KM; Margaritopoulos GA; Goh NS; Karagiannis K; Desai SR; Nicholson AG; Siafakas NM; Coghlan JG; Denton CP; Hansell DM; Wells AU
Arthritis Rheumatol; 2016 Apr; 68(4):1004-12. PubMed ID: 26636545
[TBL] [Abstract][Full Text] [Related]
24. Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis.
Yamakawa H; Hagiwara E; Kitamura H; Yamanaka Y; Ikeda S; Sekine A; Baba T; Iso S; Okudela K; Iwasawa T; Takemura T; Kuwano K; Ogura T
PLoS One; 2016; 11(8):e0161908. PubMed ID: 27564852
[TBL] [Abstract][Full Text] [Related]
25. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
Tashkin DP; Volkmann ER; Tseng CH; Kim HJ; Goldin J; Clements P; Furst D; Khanna D; Kleerup E; Roth MD; Elashoff R
Ann Rheum Dis; 2016 Feb; 75(2):374-81. PubMed ID: 25452309
[TBL] [Abstract][Full Text] [Related]
26. A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study.
Jee AS; Stewart I; Youssef P; Adelstein S; Lai D; Hua S; Stevens W; Proudman S; Ngian GS; Glaspole IN; Moodley YP; Bleasel JF; Macansh S; Nikpour M; Sahhar J; Corte TJ;
Arthritis Rheumatol; 2023 Aug; 75(8):1424-1433. PubMed ID: 36908055
[TBL] [Abstract][Full Text] [Related]
27. Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease.
Løkke A; Castello L; Pinheiro Martins P; Soulard S; Hilberg O
Adv Ther; 2023 Dec; 40(12):5502-5518. PubMed ID: 37837527
[TBL] [Abstract][Full Text] [Related]
28. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
Garin MC; Highland KB; Silver RM; Strange C
J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
[TBL] [Abstract][Full Text] [Related]
29. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
Le Gouellec N; Duhamel A; Perez T; Hachulla AL; Sobanski V; Faivre JB; Morell-Dubois S; Lambert M; Hatron PY; Hachulla E; Béhal H; Matran R; Launay D; Remy-Jardin M
PLoS One; 2017; 12(8):e0181692. PubMed ID: 28763468
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic Regulation of Profibrotic Macrophages in Systemic Sclerosis-Associated Interstitial Lung Disease.
Papazoglou A; Huang M; Bulik M; Lafyatis A; Tabib T; Morse C; Sembrat J; Rojas M; Valenzi E; Lafyatis R
Arthritis Rheumatol; 2022 Dec; 74(12):2003-2014. PubMed ID: 35849803
[TBL] [Abstract][Full Text] [Related]
31. miR-155 in the progression of lung fibrosis in systemic sclerosis.
Christmann RB; Wooten A; Sampaio-Barros P; Borges CL; Carvalho CR; Kairalla RA; Feghali-Bostwick C; Ziemek J; Mei Y; Goummih S; Tan J; Alvarez D; Kass DJ; Rojas M; de Mattos TL; Parra E; Stifano G; Capelozzi VL; Simms RW; Lafyatis R
Arthritis Res Ther; 2016 Jul; 18(1):155. PubMed ID: 27377409
[TBL] [Abstract][Full Text] [Related]
32. Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung Fibrosis.
Bogatkevich GS; Atanelishvili I; Bogatkevich AM; Silver RM
Arthritis Rheumatol; 2023 Mar; 75(3):438-448. PubMed ID: 36103378
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
[TBL] [Abstract][Full Text] [Related]
34. Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertension.
Mismetti V; Delavenne X; Montani D; Bezzeghoud S; Delezay O; Hodin S; Launay D; Marchand-Adam S; Nunes H; Ollier E; Reynaud-Gaubert M; Pastre J; Traclet J; Quetant S; Zeghmar S; Bertoletti L; Cottin V
Respir Res; 2023 Nov; 24(1):273. PubMed ID: 37936223
[TBL] [Abstract][Full Text] [Related]
35. Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.
Sun H; Zhu Y; Pan H; Chen X; Balestrini JL; Lam TT; Kanyo JE; Eichmann A; Gulati M; Fares WH; Bai H; Feghali-Bostwick CA; Gan Y; Peng X; Moore MW; White ES; Sava P; Gonzalez AL; Cheng Y; Niklason LE; Herzog EL
Arthritis Rheumatol; 2016 May; 68(5):1251-61. PubMed ID: 26749424
[TBL] [Abstract][Full Text] [Related]
36. ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF.
Durheim MT; Hoffmann-Vold AM; Eagan TM; Hovden AO; Lund MB; Bjerke G; Birring SS; Jonassen TM; Johansen OE; Sjåheim T
BMJ Open Respir Res; 2020 Jun; 7(1):. PubMed ID: 32576559
[TBL] [Abstract][Full Text] [Related]
37. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.
Wu W; Jordan S; Becker MO; Dobrota R; Maurer B; Fretheim H; Ye S; Siegert E; Allanore Y; Hoffmann-Vold AM; Distler O
Ann Rheum Dis; 2018 Sep; 77(9):1326-1332. PubMed ID: 29875097
[TBL] [Abstract][Full Text] [Related]
38. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
[TBL] [Abstract][Full Text] [Related]
39. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
Goh NS; Hoyles RK; Denton CP; Hansell DM; Renzoni EA; Maher TM; Nicholson AG; Wells AU
Arthritis Rheumatol; 2017 Aug; 69(8):1670-1678. PubMed ID: 28426895
[TBL] [Abstract][Full Text] [Related]
40. Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.
Stock CJW; De Lauretis A; Visca D; Daccord C; Kokosi M; Kouranos V; Margaritopoulos G; George PM; Molyneaux PL; Nihtyanova S; Chua F; Maher TM; Ong V; Abraham DJ; Denton CP; Wells AU; Wain LV; Renzoni EA
Clin Rheumatol; 2020 Apr; 39(4):1173-1179. PubMed ID: 31916109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
